Imperial College London

Academic Institute

Ceire Costelloe - Chief Investigator - Imperial College LondonLucy Miller - Corresponding Applicant - Imperial College LondonJulie Robotham - Collaborator - Public Health EnglandKoen Pouwels - Collaborator - University of OxfordThomas Beaney - Collaborator - Imperial College London

CPRD691

Antibiotic consumption is a crucial driver of antimicrobial resistance (AMR). Within England, most antibiotic prescribing occurs within primary care, with the majority prescribed for respiratory conditions, of which viruses cause many. Therefore, viral vaccination programmes hold promise as an intervention that can also optimise antibiotic use. Respiratory Syncytial Virus (RSV) is a leading cause of respiratory tract infections (RTI) in young children and older adults. While some health-economic evaluations exist for RSV vaccines currently under development, these studies ignored the potential impact on antibiotic use and resistance.

Background: Respiratory Syncytial Virus (RSV) is associated with high healthcare utilisation and antibiotic prescribing within England. Therefore, RSV vaccines could act as an intervention to reduce RSV burden and support antibiotic use optimisation. Reduction of antibiotic use in primary care is a cornerstone of antimicrobial stewardship interventions aiming to curb the rise in AMR. Quantification of the impact of RSV vaccines on AMR does not exist. More research is required to inform cost-effectiveness models of RSV vaccines that can include AMR outcomes. RSV primary care antibiotic prescribing by antibiotic type and RSV healthcare utilisation that includes A&E attendances, outpatient appointments and associated costs for all age groups is unknown.

09/03/2021

Release